Subscribe to our newsletter to receive the latest product updates and special offers

HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

OTLK

Outlook Therapeutics Inc

Last Close
May 17 • 04:00PM ET
7.78
Dollar change
+0.45
Percentage change
6.14 		%
Held by: VTI IWM VXF IWO VTWO IWC VTWG RYLD IWV VTHR Scroll to Statements
IndexRUT P/E- EPS (ttm)-11.48 Insider Own29.33% Shs Outstand23.41M Perf Week2.64%
Market Cap182.13M Forward P/E- EPS next Y-2.48 Insider Trans0.95% Shs Float16.54M Perf Month-6.15%
Income-159.13M PEG- EPS next Q-1.04 Inst Own32.29% Short Float7.61% Perf Quarter-13.86%
Sales0.00M P/S- EPS this Y-29.35% Inst Trans-24.34% Short Ratio1.84 Perf Half Y-12.82%
Book/sh-6.10 P/B- EPS next Y60.06% ROA-281.52% Short Interest1.26M Perf Year-67.58%
Cash/sh2.02 P/C3.86 EPS next 5Y- ROE-827.71% 52W Range4.00 - 40.60 Perf YTD-1.27%
Dividend Est.- P/FCF- EPS past 5Y52.49% ROI- 52W High-80.84% Beta0.65
Dividend TTM- Quick Ratio1.07 Sales past 5Y12.77% Gross Margin- 52W Low94.31% ATR (14)0.63
Dividend Ex-Date- Current Ratio1.07 EPS Y/Y TTM-128.91% Oper. Margin0.00% RSI (14)44.35 Volatility7.46% 6.51%
Employees24 Debt/Eq- Sales Y/Y TTM- Profit Margin- Recom1.14 Target Price38.86
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q-1444.33% Payout- Rel Volume0.27 Prev Close7.33
Sales Surprise- EPS Surprise-70.35% Sales Q/Q- EarningsMay 16 BMO Avg Volume685.29K Price7.78
SMA20-4.32% SMA50-6.85% SMA200-22.15% Trades Volume185,159 Change6.14%
Date Action Analyst Rating Change Price Target Change
Mar-27-24Upgrade BTIG Research Neutral → Buy $50
Feb-15-24Upgrade Chardan Capital Markets Neutral → Buy $3
Jan-25-24Upgrade Guggenheim Neutral → Buy
Dec-27-23Upgrade CapitalOne Equal Weight → Overweight $5
Aug-31-23Downgrade H.C. Wainwright Buy → Neutral $5 → $1
Aug-31-23Downgrade Chardan Capital Markets Buy → Neutral
Aug-30-23Downgrade Guggenheim Buy → Neutral
Aug-30-23Downgrade CapitalOne Overweight → Equal Weight
Aug-30-23Downgrade Cantor Fitzgerald Overweight → Neutral $4.50 → $1
Aug-30-23Downgrade BTIG Research Buy → Neutral
Show Previous Ratings
May-17-24 04:27AM
Q2 2024 Outlook Therapeutics Inc Earnings Call
(Thomson Reuters StreetEvents) +6.14%
May-15-24 10:53PM
OTLK Stock Earnings: Outlook Therapeutics Misses EPS for Q2 2024
(InvestorPlace)
05:00PM
Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate Update
(GlobeNewswire)
May-13-24 11:18AM
Outlook Therapeutics Submits Marketing Application for Wet Age-related Macular Degeneration Therapy in UK
(MT Newswires)
08:50AM
Outlook Therapeutics Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD
(GlobeNewswire)
08:45AM Loading…
May-09-24 08:45AM
Outlook Therapeutics to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and Webcast
(GlobeNewswire)
May-02-24 09:05AM
Outlook Therapeutics to Present at the Retina World Congress 2024
(GlobeNewswire)
Apr-29-24 09:00AM
Outlook Therapeutics to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase
(GlobeNewswire) +7.95%
Apr-26-24 06:37AM
Marriott Vacations, Carrols Restaurant Group, and More Stocks See Action From Activist Investors
(Barrons.com)
Apr-15-24 04:15PM
Outlook Therapeutics Announces Closing of Private Placement of $5.0 Million
(GlobeNewswire)
12:54PM
Biotech on a Budget: 7 Stocks Under $10 With Huge Potential
(InvestorPlace)
Apr-10-24 03:30PM
Insiders are Piling into These 10 Healthcare Stocks in 2024
(Insider Monkey)
Mar-22-24 07:35AM
Outlook Therapeutics Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD
(GlobeNewswire) +22.59%
Mar-18-24 05:10PM
Outlook Therapeutics Announces Closing of Private Placement of up to $159 Million
(GlobeNewswire) -5.52%
Mar-12-24 08:05AM
Outlook Therapeutics Announces Effective Date for 1-for-20 Reverse Stock Split
(GlobeNewswire) -10.57%
03:36PM Loading…
Mar-06-24 03:36PM
7 of the Best Speculative Stocks You Can Snag for Less Than $1
(InvestorPlace)
Feb-25-24 01:37PM
7 Biotech Penny Stocks on the Verge of Clinical Trial Victory
(InvestorPlace)
Feb-14-24 05:27PM
Outlook Therapeutics Inc (OTLK) Reports Q1 Fiscal 2024 Results and Strategic Developments
(GuruFocus.com) +5.08%
08:05AM
Outlook Therapeutics Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corporate Update
(GlobeNewswire)
Jan-31-24 08:05AM
Outlook Therapeutics Doses First Subject in NORSE EIGHT
(GlobeNewswire) -6.99%
Jan-24-24 08:06AM
Outlook (OTLK) Surges 31% on Regulatory Update for AMD Study
(Zacks) -9.87%
Jan-23-24 08:00AM
Outlook Therapeutics Receives FDA Agreement Under Special Protocol Assessment (SPA) for 90 Day Non-Inferiority Study, NORSE EIGHT, and Announces Private Placement of Up to $172 Million to Advance ONS-5010
(GlobeNewswire) +30.53%
Jan-02-24 10:18PM
Outlook Therapeutics Investors: Company Investigated by the Portnoy Law Firm
(GlobeNewswire)
Dec-27-23 02:03PM
OTLK Stock Earnings: Outlook Therapeutics Reported Results for Q4 2023
(InvestorPlace)
09:30AM
OUTLOOK SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Outlook To Contact Him Directly To Discuss Their Options
(GlobeNewswire)
Dec-26-23 02:15PM
January 2. 2024 Lawsuit Deadline: Investors who lost over $200,000 with Outlook Therapeutics, Inc. (NASDAQ: OTLK) shares should contact the Shareholders Foundation
(GlobeNewswire) +5.41%
Dec-22-23 08:05AM
Outlook Therapeutics Reports Financial Results for Fiscal Year 2023 and Reiterates ONS-5010 Clinical and Regulatory Path Forward in the U.S. and EU
(GlobeNewswire)
Dec-19-23 08:05AM
Outlook Therapeutics Submits Special Protocol Assessment (SPA) to FDA for Non-Inferiority Study of ONS-5010
(GlobeNewswire) +9.73%
Dec-06-23 08:05AM
Outlook Therapeutics Announces Strategic Organizational Realignment
(GlobeNewswire)
Nov-27-23 08:05AM
Outlook Therapeutics Announces Receipt of Type A Meeting Minutes and Reiterates Regulatory Path Forward for ONS-5010
(GlobeNewswire)
06:30AM Loading…
06:30AM
OTLK INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Outlook Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Case
(GlobeNewswire)
Nov-15-23 02:04PM
OTLK STOCKHOLDERS: Contact Robbins LLP for Information About Your Rights Against Outlook Therapeutics, Inc.
(Business Wire)
Nov-14-23 08:05AM
Outlook Therapeutics Adds Global Commercial Expertise with Appointment of Jedd Comiskey as Senior VP - Head of Europe
(GlobeNewswire) +8.83%
Nov-09-23 08:52AM
12 Best Day Trading Stocks To Buy
(Insider Monkey) -11.00%
Nov-02-23 08:05AM
Outlook Therapeutics Provides Update on Type A Meetings with FDA
(GlobeNewswire) -46.24%
Nov-01-23 08:05AM
Outlook Therapeutics to Present at Guggenheim's 5th Annual Inflammation, Neurology & Immunology (INI) Conference
(GlobeNewswire) +5.40%
Oct-17-23 05:22PM
Outlook Therapeutics Investors: Company Investigated by the Portnoy Law Firm
(GlobeNewswire) +14.51%
Oct-11-23 05:49PM
Outlook Therapeutics Investors: Company Investigated by the Portnoy Law Firm
(GlobeNewswire)
Sep-29-23 08:05AM
Outlook Therapeutics Requests Type A Meeting With FDA
(GlobeNewswire)
Sep-21-23 08:05AM
Outlook Therapeutics® to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
(GlobeNewswire)
Sep-05-23 08:05AM
Outlook Therapeutics® to Present at the H.C. Wainwright 25th Annual Global Investment Conference
(GlobeNewswire)
Aug-31-23 10:15AM
Biotech Stock Roundup: FGEN Down on Study Failure, BMY Drug's Label Expansion & More
(Zacks) -15.08%
Aug-30-23 06:11AM
US FDA declines to approve Outlook Therapeutics' eye disease drug
(Reuters) -80.96%
06:00AM
Outlook Therapeutics® Provides Regulatory Update on FDA Review of ONS-5010 / LYTENAVA (bevacizumab-vikg) for the Treatment of Wet AMD
(GlobeNewswire)
Aug-28-23 11:47AM
Outlook Therapeutics (OTLK): A Deep Dive into its Overvalued Status
(GuruFocus.com) +10.34%
Aug-14-23 09:55AM
Should You Buy Outlook Therapeutics (OTLK) Ahead of Earnings?
(Zacks)
08:05AM
Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2023 and Reiterates Key Anticipated Near-Term Milestones
(GlobeNewswire)
Aug-01-23 08:45AM
Outlook Therapeutics® to Present at the BTIG Virtual Biotechnology Conference 2023
(GlobeNewswire)
Jun-11-23 08:45AM
When Will Outlook Therapeutics, Inc. (NASDAQ:OTLK) Turn A Profit?
(Simply Wall St.)
Jun-06-23 01:59PM
Why Shares of Outlook Therapeutics Rose Tuesday
(Motley Fool)
May-15-23 08:05AM
Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2023 and Provides Corporate Update
(GlobeNewswire)
Apr-27-23 08:05AM
Outlook Therapeutics® to Present at the H.C. Wainwright BioConnect Investor Conference
(GlobeNewswire)
Apr-10-23 11:43AM
Outlook Therapeutics, Inc.'s (NASDAQ:OTLK) top owners are individual investors with 37% stake, while 27% is held by private equity firms
(Simply Wall St.)
Mar-13-23 07:00AM
Outlook Therapeutics® Confirms It Has No Exposure to Silicon Valley Bank
(GlobeNewswire)
Feb-14-23 08:05AM
Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2023 and Provides Corporate Update
(GlobeNewswire)
Feb-07-23 08:05AM
Outlook Therapeutics® to Present at the SVB Securities Global Biopharma Conference
(GlobeNewswire)
Jan-19-23 08:05AM
Outlook Therapeutics® Strengthens Medical Affairs and Commercial Expertise with Appointments of Surendra Sharma, MD, Senior Vice President of Medical Affairs and Glen Olsheim, Executive Director of Commercial Excellence
(GlobeNewswire)
Jan-11-23 01:00PM
JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th
(ACCESSWIRE)
Jan-09-23 08:05AM
Outlook Therapeutics® to Present at the Virtual Investor 2023 Companies to Watch Event
(GlobeNewswire)
Jan-02-23 07:31AM
Breakeven On The Horizon For Outlook Therapeutics, Inc. (NASDAQ:OTLK)
(Simply Wall St.)
Dec-29-22 09:05AM
Outlook Therapeutics® Reports Financial Results for Fiscal Year 2022 and Provides Corporate Update
(GlobeNewswire) +5.94%
Dec-23-22 09:00AM
Outlook Therapeutics® Enters Definitive Agreement for $31.8 Million Unsecured Convertible Promissory Note
(GlobeNewswire) +21.81%
06:00AM
Outlook Therapeutics Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
(GlobeNewswire)
Dec-22-22 08:05AM
Outlook Therapeutics® Announces Validation of Marketing Authorization Application by the European Medicines Agency for ONS-5010 as a Treatment for Wet AMD
(GlobeNewswire)
Dec-01-22 08:05AM
Outlook Therapeutics® to Participate in the Cantor Fitzgerald Medical & Aesthetic Dermatology, Ophthalmology & Medtech Conference
(GlobeNewswire)
Nov-22-22 08:05AM
Outlook Therapeutics® to Present at the BTIG Ophthalmology Day
(GlobeNewswire)
Nov-01-22 09:55AM
Outlook Therapeutics, Inc.'s (NASDAQ:OTLK) top owners are individual investors with 38% stake, while 25% is held by private equity firms
(Simply Wall St.)
Oct-28-22 08:05AM
Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD
(GlobeNewswire) -9.47%
Oct-05-22 06:09AM
Independent Director Kurt Hilzinger Just Bought 33% More Shares In Outlook Therapeutics, Inc. (NASDAQ:OTLK)
(Simply Wall St.)
Sep-27-22 08:05AM
Outlook Therapeutics® and AmerisourceBergen Announce Strategic Commercialization Agreement for ONS-5010 for the Treatment of Wet AMD
(GlobeNewswire)
Sep-26-22 08:35AM
Outlook Therapeutics® to Present at Eyecelerator @ AAO 2022
(GlobeNewswire)
Sep-07-22 08:05AM
Outlook Therapeutics® to Present at the H.C. Wainwright 24th Annual Global Investment Conference
(GlobeNewswire)
Aug-30-22 09:39AM
Outlook Therapeutics Shares Pop After Filing US Application For Its Lead Eye Disease Candidate
(Benzinga)
08:05AM
Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration
(GlobeNewswire)
Aug-15-22 08:05AM
Outlook Therapeutics Strengthens Board of Directors with Appointment of Julia A. Haller, MD
(GlobeNewswire) +5.00%
Aug-10-22 08:05AM
Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2022 and Reiterates Key Anticipated Near-Term Milestones
(GlobeNewswire)
Aug-04-22 08:05AM
Outlook to Present at the H.C. Wainwright 2nd Annual Ophthalmology Conference
(GlobeNewswire)
Jul-26-22 07:18AM
When Will Outlook Therapeutics, Inc. (NASDAQ:OTLK) Become Profitable?
(Simply Wall St.)
Jul-05-22 08:05AM
Outlook Therapeutics Announces Full Cash Pre-Payment of Convertible Promissory Note
(GlobeNewswire) +7.84%
Jun-14-22 08:05AM
Outlook Therapeutics Confirms Status of Biologics License Application (BLA) Submission for ONS-5010
(GlobeNewswire) +15.95%
May-31-22 08:05AM
Outlook Therapeutics Provides Update on Biologics License Application (BLA) Submission for ONS-5010 as a Treatment for Wet AMD
(GlobeNewswire) -31.95%
May-27-22 07:25AM
Bullish Outlook Therapeutics, Inc. (NASDAQ:OTLK) insiders filled their treasuries with US$557k worth of stock over last year
(Simply Wall St.) +7.64%
May-18-22 08:05AM
Outlook Therapeutics to Present at the H.C. Wainwright Global Investment Conference
(GlobeNewswire) -6.13%
May-13-22 08:05AM
Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2022 and Provides Corporate Update
(GlobeNewswire) +7.38%
May-10-22 08:35AM
Outlook Therapeutics to Participate in Retina World Congress 2022
(GlobeNewswire)
May-09-22 08:35AM
Outlook Therapeutics to Participate at the Virtual Investor 2022 CEO Spotlight
(GlobeNewswire) -7.50%
May-04-22 12:02PM
Here's What Outlook Therapeutics, Inc.'s (NASDAQ:OTLK) Shareholder Ownership Structure Looks Like
(Simply Wall St.)
Apr-22-22 08:05AM
BioLexis Reorganization Results in GMS Holdings as Largest Shareholder in Outlook Therapeutics
(GlobeNewswire)
Apr-05-22 08:05AM
Outlook Therapeutics to Present at Wet AMD and DME Drug Development Summit
(GlobeNewswire)
Apr-04-22 07:45PM
Is Outlook Therapeutics (NASDAQ:OTLK) Using Too Much Debt?
(Simply Wall St.)
Mar-31-22 08:05AM
Outlook Therapeutics Submits Biologics License Application to the U.S. Food and Drug Administration for ONS-5010 as a Treatment for Wet AMD
(GlobeNewswire) -10.55%
Mar-03-22 08:05AM
Outlook Therapeutics Bolsters Commercialization Expertise with Appointment of Alicia Tozier as Senior Vice President of Marketing and Market Access
(GlobeNewswire) +5.29%
Feb-24-22 08:05AM
Outlook Therapeutics to Present at the RANZCO 52nd Annual Scientific Congress
(GlobeNewswire) +16.31%
Feb-16-22 10:59AM
When Will Outlook Therapeutics, Inc. (NASDAQ:OTLK) Become Profitable?
(Simply Wall St.) +7.14%
Feb-14-22 08:05AM
Outlook Therapeutics Reports Financial Results for First Quarter Fiscal Year 2022 and Provides Corporate Update
(GlobeNewswire)
Feb-10-22 08:05AM
Outlook Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference
(GlobeNewswire)
Feb-08-22 08:05AM
Outlook Therapeutics Expands Commercial Team with Appointment of Senior Vice President of Commercial Operations
(GlobeNewswire)
Feb-02-22 05:38PM
KWB Wealth Buys SPDR Portfolio S&P 600 Small Cap ETF, SPDR Portfolio Short Term Corporate ...
(GuruFocus.com) -6.71%
08:05AM
Outlook Therapeutics to Present at the Fourth Annual Telluride Retina Film Festival
(GlobeNewswire)
Jan-25-22 08:05AM
Outlook Therapeutics Provides a Corporate Update and Business Outlook
(GlobeNewswire)
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Haddadin Yezan MuntherDirectorMar 28 '24Buy11.821,88222,2425,049Mar 29 10:39 AM
Evanson JeffCHIEF COMMERCIAL OFFICERMar 07 '24Buy0.4262,48426,243808,459Mar 11 04:43 PM
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.